Extracellular vesicles for delivering therapeutic agents in ischemia/reperfusion injury DOI Creative Commons
Weihang Zhou,

Xinchi Jiang,

Jianqing Gao

et al.

Asian Journal of Pharmaceutical Sciences, Journal Year: 2024, Volume and Issue: 19(6), P. 100965 - 100965

Published: Sept. 4, 2024

Ischemia/reperfusion (I/R) injury is marked by the restriction and subsequent restoration of blood supply to an organ. This process can exacerbate initial tissue damage, leading further disorders, disability, even death. Extracellular vesicles (EVs) are crucial in cell communication releasing cargo that regulates physiological state recipient cells. The development EVs presents a novel avenue for delivering therapeutic agents I/R therapy. potential derived from stem cells, endothelial plasma has been actively investigated. Therefore, this review aims provide overview pathological biophysical properties EVs. We noted serve as nontoxic, flexible, multifunctional carriers capable intervening progression. efficacy be enhanced through various engineering strategies. Improving tropism

Language: Английский

Surface modification of extracellular vesicles with polyoxazolines to enhance their plasma stability and tumor accumulation DOI
Laurianne Simon, Julie Constanzo, Claudia Terraza‐Aguirre

et al.

Biomaterials, Journal Year: 2024, Volume and Issue: 313, P. 122748 - 122748

Published: Aug. 5, 2024

Language: Английский

Citations

7

Aberrant Activation of Immune and Non-Immune Cells Contributes to Joint Inflammation and Bone Degradation in Rheumatoid Arthritis DOI Open Access
Kutty Selva Nandakumar, Qinghua Fang,

Isabella Wingbro Ågren

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(21), P. 15883 - 15883

Published: Nov. 1, 2023

Abnormal activation of multiple immune and non-immune cells proinflammatory factors mediate the development joint inflammation in genetically susceptible individuals. Although specific environmental like smoking infections are associated with disease pathogenesis, until now, we did not know autoantigens arthritogenic that trigger initiation clinical disease. Autoantibodies recognizing post-translationally modified unmodified antigens generated circulation before onset disease, could serve as diagnostic prognostic markers. The characteristic features autoantibodies change regarding sub-class, affinity, glycosylation pattern, epitope spreading onset. Some these antibodies were proven to be pathogenic using animal cell-culture models. However, all them can induce animals. This review discusses aberrant major contributing inflammation. Recent studies explored protective effects extracellular vesicles from mesenchymal stem bacteria on joints by targeting pathways. Current therapeutics clinics target inflammatory pathways attenuate protect cartilage bones degradation, but none cure Hence, more basic research is needed investigate triggers mechanisms involved initiating relapses prevent chronic damaging architecture.

Language: Английский

Citations

14

Allogenic bone marrow–derived mesenchymal stromal cell–based therapy for patients with chronic low back pain: a prospective, multicentre, randomised placebo controlled trial (RESPINE study) DOI Creative Commons
Yves‐Marie Pers,

Robert Soler-Rich,

Gianluca Vadalà

et al.

Annals of the Rheumatic Diseases, Journal Year: 2024, Volume and Issue: 83(11), P. 1572 - 1583

Published: Oct. 11, 2024

Objectives

To assess the efficacy of a single intradiscal injection allogeneic bone marrow mesenchymal stromal cells (BM-MSCs) versus sham placebo in patients with chronic low back pain (LBP).

Methods

Participants were randomised prospective, double-blind, controlled study to receive either or 20 million BM-MSC, between April 2018 and December 2022. The first co-primary endpoint was rate responders defined by improvement Visual Analogue Scale (VAS) for at least 20% mm, Oswestry Disability Index (ODI) baseline month 12. secondary structural assessed disc fluid content measured quantitative MRI T2, Secondary endpoints included VAS, ODI, Short Form (SF)-36 minimal clinically important difference all timepoints (1, 3, 6, 12 24 months). We determined immune response associated cell 6 months. Serious adverse events (SAEs) recorded.

Results

114 (n=58, BM-MSC group; n=56, group). At months, primary outcome not reached (74% group vs 69% p=0.77). groups did differ outcomes. No SAE related intervention occurred.

Conclusions

While our conclusively demonstrate BM-MSCs LBP, procedure safe. Long-term outcomes MSC therapy LBP are still being studied.

Trial registration number

EudraCT 2017-002092-25/ClinicalTrials.gov: NCT03737461.

Language: Английский

Citations

6

Extracellular Vesicle Spherical Nucleic Acids DOI Creative Commons
Hao Chen,

Qiaojiao Ding,

Lin Li

et al.

JACS Au, Journal Year: 2024, Volume and Issue: 4(6), P. 2381 - 2392

Published: May 30, 2024

Extracellular vesicles (EVs) are naturally occurring secreted by cells that can transport cargo between cells, making them promising bioactive nanomaterials. However, due to the complex and heterogeneous biological characteristics, a method for robust EV manipulation efficient delivery is still lacking. Here, we developed novel class of extracellular vesicle spherical nucleic acid (EV-SNA) nanostructures with scalability, programmability, cellular delivery. EV-SNA was constructed through simple hydrophobic coassembly natural EVs cholesterol-modified oligonucleotides be stable 1 month at room temperature. Based on programmable shells, respond AND logic gates achieve assembly manipulation. Importantly, from wide range sources EV, enhancing capability nearly 10–20 times. Compared artificial liposomal SNA, endogenous exhibited better biocompatibility more effective antisense in hard-to-transfect primary stem cells. Additionally, deliver functional immune regulation. As material form, may provide modular framework paradigm EV-based applications drug delivery, disease treatment, nanovaccines, other fields.

Language: Английский

Citations

4

Cell dehydration enables massive production of engineered membrane vesicles with therapeutic functions DOI Creative Commons
Jie Liu, Tingting Shen, Yu Zhang

et al.

Journal of Extracellular Vesicles, Journal Year: 2024, Volume and Issue: 13(7)

Published: July 1, 2024

Abstract Extracellular vesicles (EVs) have emerged as promising biomaterials for the treatment of different disease. However, only handful types EVs with clinical transformation potential been reported to date, and their preparation on a large scale under biosafety‐controlled conditions is limited. In this study, we characterize novel type EV application potential: dehydration‐induced extracellular (DIMVs). DIMV micron‐diameter cell vesicle that contains more bioactive molecules, such proteins RNA, but not DNA, than previously vesicles. The extraordinarily straightforward, which possesses high level biosafety, protein utilization ratio roughly 600 times greater naturally secreted EVs. Additional experiments demonstrate viability pre‐ or post‐isolation modification, including gene editing, nucleic acid encapsulation surface anchoring, size adjustment. Finally, animal models, directly show biosafety immunogenicity DIMV, investigate its tumour vaccine drug carrier in cancer treatment.

Language: Английский

Citations

4

Engineered extracellular vesicles: an emerging nanomedicine therapeutic platform DOI

Jingshi Tang,

Dezhong Li, Rui Wang

et al.

Chemical Communications, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Extracellular vesicles have been deemed as potential drug carriers for treatment of various diseases. Recent advances summarized, including the sources, delivery function, extraction and cargo-loading technology extracellular vesicles.

Language: Английский

Citations

0

Apoptotic Vesicles Derived from Mesenchymal Stem Cells Ameliorate Hypersensitivity Responses via Inducing CD8+ T Cells Apoptosis with Calcium Overload and Mitochondrial Dysfunction DOI Creative Commons
Anqi Liu,

Peng Peng,

Changze Wei

et al.

Advanced Science, Journal Year: 2025, Volume and Issue: unknown

Published: March 16, 2025

Abstract Apoptosis is crucial for maintaining internal homeostasis. Apoptotic vesicles (ApoVs) derived from mesenchymal stem/ stromal cells (MSCs‐ApoVs) as natural lipid nanoparticles are attractive candidates the next generation of immunotherapies. However, therapeutic potential MSCs‐ApoVs in managing hypersensitivity reactions mediated by CD8 + T remains elusive. This research utilized contact and oral lichenoid reaction models, both which represent type IV reactions. ApoVs shown that stem human exfoliated deciduous teeth (SHED‐ApoVs), a subtype MSCs, directly fused with plasma membrane cells, subsequently increasing permeability through L‐type voltage‐gated Ca 2+ channels. initiates cascade events including calcium overload, mitochondrial dysfunction, initiation apoptosis these cells. As known, this first study to characterize SHED‐ApoVs immune microenvironment modulators, demonstrating their mechanism Moreover, analysis blood samples patients verified antihypersensitivity property SHED‐ApoVs. sheds light on prospects underlying mechanisms diseases contributing novel perspectives clinical application nanovesicle‐based cell‐free therapies.

Language: Английский

Citations

0

Immune mediated inflammatory diseases: moving from targeted biologic therapy, stem cell therapy to targeted cell therapy DOI Creative Commons
Zhihou Liang, Hui Xie, Dongze Wu

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: April 7, 2025

Despite the advancements in targeted biologic therapy for immune-mediated inflammatory diseases (IMIDs), significant challenges persist, including drug maintenance, primary and secondary non-responses, adverse effects. Recent data have strengthened evidence supporting stem cell as an experimental salvage into a standard treatment option. preclinical clinical studies suggested that chimeric antigen receptor T (CAR-T) therapy, which depleting tissue bone marrow B cells, may lead to improvement, even inducing long-lasting remissions patients with IMIDs. In this review, we address unmet needs of delineate critical differences between transplantation CAR-T evaluate current status IMIDs explore its potential existing limitations.

Language: Английский

Citations

0

Immune regulation and repair of osteochondral defects using manganese-luteolin hydrogel scaffold DOI
Shuai Yuan, Haobo Li, Zhengyang Xu

et al.

Journal of Controlled Release, Journal Year: 2025, Volume and Issue: unknown, P. 113920 - 113920

Published: May 1, 2025

Language: Английский

Citations

0

Emerging Therapy in Osteoarthritis: Mesenchymal Stem Cells, Secretomes, and Using Hydrogels to Enhance Efficacy DOI

Qi-Ming Pang,

Jingdi Zhan,

Zhuolin Chen

et al.

BioDrugs, Journal Year: 2025, Volume and Issue: unknown

Published: May 30, 2025

Language: Английский

Citations

0